Xconomy | San Diego - Business + Technology in the Exponential Economy

Sequenom Licenses IP for Maternal Urine Tests

Sequenom (NASDAQ:SQNM), a San Diego-based provider of molecular diagnostics, reports that it has licensed exclusive rights from Monmouth Junction, NJ, diagnostics firm Xenomics (PINK:XNOM) to U.S. and European patents that cover the use of fetal DNA fragments found in a mother’s urine for prenatal diagnostics and research. As Luke discusses in this story, Sequenom is already deep into development of prenatal diagnostics that capture fetal DNA fragments from mothers’ blood samples.

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.

Comments | Reprints | Share: